Servier chooses Pall as Exclusive Technology and Services Provider for new Biomanufacturing Facility

InfoWeb Marketplace

Thursday, July 18, 2019Description :
End-to-end solutions from Pall Biotech will be implemented for the development and manufacturing of monoclonal antibodies (mAbs) and recombinant proteins, resulting in increased speed to market and reduced customer costs. The facility is part of the Bio-S project at Servier focused on delivering best-in-class support for oncology drug production from research and development (R&D) to clinical scale. Learn more at https://biotech.pall.com/en/press-release/pall-corporation-chosen-as-supplier-for-servier-biomanufacturing-faciility-france.html

Grouped quotes (0)